How much does the domestic trametinib targeted drug cost in 2024?

Currently, there is no domestically produced trametinib (Trametinib) on the market in China. The domestically produced trametinib is an imported drug and is produced by Novartis Pharmaceuticals. Trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma who have a BRAF V600E or BRAF V600K mutation detected by an FDA-approved test. Trametinib is not suitable for the treatment of patients who have previously received a BRAF inhibitor.

The approval of trametinib was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, international, open-label, randomized, active-controlled trial. Approximately 50% of patients with cutaneous melanoma have BRAF gene mutations. Concurrently with the approval of dabrafenib and trametinib, the FDA approved the THxID BRAF test for the detection of BRAF V600E and BRAF V600K mutations. Trametinib is a tyrosine kinase inhibitor that inhibits the growth and spread of tumor cells by binding to these fusion proteins and blocking their activity.

The original drug Trametinib that is marketed in China has been included in the scope of medical insurance, and is only available for reimbursement to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000, while the original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 2mg*30 tablets produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.